The Role of Pre-Clinical Bleomycin Models in IPF Drug Development 

In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D, to provide our collective thoughts on the use and value of the pre-clinical bleomycin model in drug development for Idiopathic Pulmonary Fibrosis (IPF).  IPF is a progressive lung disease with […]

Reflections from ECM2022, Copenhagen, July 2022

The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of this three-day meeting was very much on the role of collagens and other extra-cellular matrix components in health and disease. What did we learn?   A lot about the basic structure and function of matrix proteins, […]

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.